GMAB · Genmab ADR
United States · RS rating 98 · As of 2026-11-03
| Price | 55.52 USD |
|---|---|
| 1-day change | +1.1% |
| RS rating (overall / 1M / 3M / 12M) | 98 / 98 / 97 / 93 |
| Stage | Advancing |
| Composite / Minervini / CANSLIM score | 70 / 76 / 55 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +491.6% |
| Sales growth Q/Q | +3.5% |
| Distance from 52-week high | +3.1% |
| Market cap (USD) | $16.6B |